Pratyush Kumar Sahoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pratyush Kumar Sahoo has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jyothilakshmi Sajimon
Centre for Human Genetics, India
1 shared publication - Neeha Sinai Borker
Centre for Human Genetics, India
1 shared publication - Radhika Nair
Centre for Human Genetics, India
1 shared publication - Rifat Aara
Centre for Human Genetics, India
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by MDPI AG in Preprints.org
From Molecular Escape to Clinical Relapse: Convergent Adaptive Programs and the Case for Predictive Oncology in Breast Cancer
Breast cancer therapy has advanced substantially over the past two decades, yet disease recurrence and metastatic progression remain the leading causes of mortality. Resistance in hormone receptor-positive (HR+), HER2-positive, and Triple-negative (TNBC) disease is conventionally treated as three separate, each driven by its own escape route. This review suggests that resistance across all three subtypes instead converges on a shared, limited set of adaptive programs: epithelial-mesenchymal plasticity, cancer stem cell enrichment, metabolic rewiring, and microenvironment-mediated immune evasion. We trace the stage-wise clinical trajectory and dominant point of failure within each subtype, then examine how large-cohort genomics, single-cell transcriptomics, circulating tumour DNA, and machine learning have exposed this convergence, and the barriers still limiting its clinical use. To move beyond a purely mechanistic argument, we present an exploratory analysis stratifying overall survival within each subtype by which adaptive program dominates the resistant tumour. EMT enrichment in TNBC, immune evasion in HR-positive disease, and metabolic rewiring in HER2-positive disease. Although based on modest cohorts, this pattern suggests the four programs are genuinely different drawing on a shared cellular toolkit, rather than interchangeable descriptions of the same biology, and supports testing metabolic-program enrichment as a maintenance biomarker in HER2-positive disease. Closing the gap between mechanistic knowledge and clinical practice will require replacing subtype-exclusive resistance biomarkers with subtype anchored program-specific panels deployed alongside the standard clinical panel, shifting management from a model that reacts to resistance toward one that anticipates it.
- 9 September 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Molecular Escape to Clinical Relapse: Convergent Adaptive Programs and the Case for Predictive Oncology in Breast Cancer
Breast cancer therapy has advanced substantially over the past two decades, yet disease recurrence and metastatic progression remain the leading causes of mortality. Resistance in hormone receptor-positive (HR+), HER2-positive, and Triple-negative (TNBC) disease is conventionally treated as three separate, each driven by its own escape route. This review suggests that resistance across all three subtypes instead converges on a shared, limited set of adaptive programs: epithelial-mesenchymal plasticity, cancer stem cell enrichment, metabolic rewiring, and microenvironment-mediated immune evasion. We trace the stage-wise clinical trajectory and dominant point of failure within each subtype, then examine how large-cohort genomics, single-cell transcriptomics, circulating tumour DNA, and machine learning have exposed this convergence, and the barriers still limiting its clinical use. To move beyond a purely mechanistic argument, we present an exploratory analysis stratifying overall survival within each subtype by which adaptive program dominates the resistant tumour. EMT enrichment in TNBC, immune evasion in HR-positive disease, and metabolic rewiring in HER2-positive disease. Although based on modest cohorts, this pattern suggests the four programs are genuinely different drawing on a shared cellular toolkit, rather than interchangeable descriptions of the same biology, and supports testing metabolic-program enrichment as a maintenance biomarker in HER2-positive disease. Closing the gap between mechanistic knowledge and clinical practice will require replacing subtype-exclusive resistance biomarkers with subtype anchored program-specific panels deployed alongside the standard clinical panel, shifting management from a model that reacts to resistance toward one that anticipates it.